Results 151 to 160 of about 1,466,333 (379)

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

iScience
Summary: A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, Yuko Okemoto-Nakamura, Yoshimi Shimizu, Motohiko Ogawa, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Mika K. Kaneko, Masayoshi Fukasawa, Yukinari Kato, Kohji Noguchi   +12 more
doaj  

Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus [PDF]

, 2013
Dengue viruses are the most common arthropod-transmitted viral infection, with an estimated 390 million human infections annually and ∼3.6 billion people at risk.
Brien, James D, Diamond, Michael S, Harris, Eva, Johnson, Syd, Lam, Chia-Ying Kao, Schmid, Michael A, Sukupolvi-Petty, Soila, Williams, Katherine L   +7 more
core   +2 more sources

Anti-CD3:anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro. [PDF]

, 1993
James A. MacLean, Zhen Su, Y. Guo, M S Sy, R B Colvin, Johnson T. Wong   +5 more
openalex   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Furmonertinib in uncommon EGFR‐mutated non‐small cell lung cancer with central nervous system metastases: A retrospective cohort study

International Journal of Cancer, EarlyView.
What's New? Mutations in EGFR are the most frequently detected driver mutations in non‐small cell lung carcinoma (NSCLC), and two common mutations account for 75%–90% of these. The remaining 10%–25% are uncommon mutations, a heterogeneous set of genetic changes that do not necessarily respond well to treatment.
Yuwen Xie, Hehui Fang, Wanwan Cheng, Ting Xu, Shu Xu, Chuanyong Yu, Yong Liu, Shencun Fang   +7 more
wiley   +1 more source

The evolution of bispecific antibodies [PDF]

Expert Opinion on Biological Therapy, 2022
openaire   +2 more sources

Dual specificity antibodies using a double-stranded oligonucleotide bridge [PDF]

The covalent conjugation of oligonucleotides to antibody Fab’ fragments was optimized by using oligonucleotides modified with a hexaethylene linker arm bearing three amino groups.
Bos, Carter, Dekruif, Eriksson, Fernandez-Sesma, George Panayotou, Ivan M. Roitt, Jurivich, Keler, Klonisch, Klonisch, Kuijpers, Maia, Michael Bartlet-Jones, Neri, Peter J. Delves, Pluckthun, Schott, Thomas Klonisch, Torben Lund, van de Winkel, Zahida N. Chaudri   +21 more
core   +1 more source

Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. [PDF]

, 1991
Jan Brissinck, C. Demanet, M. Moser, Oberdan Léo, K Thielemans   +4 more
openalex   +1 more source

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinion

International Journal of Cancer, EarlyView.
What's New? Emerging strategies for the treatment of advanced non‐small cell lung cancer (NSCLC) featuring epidermal growth factor receptor (EGFR) mutations are helping improve patient outcomes. Which strategies are optimal to effectively manage EGFR‐mutant NSCLC, however, remains unclear.
Gee‐Chen Chang, Akhil Kapoor, Chee Khoon Lee, Chunxia Su, Daniel Chan, Guia Elena Imelda Ladrera, Hye Ryun Kim, Mostafa Aziz Sumon, Moushumi Suryavanshi, Sita Andarini, Tatsuya Yoshida, Thanyanan Reungwetwattana, Tuan Khoi Nguyen, Pei Jye Voon   +13 more
wiley   +1 more source

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation

Frontiers in Immunology
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu, Oana Hangiu, Oana Hangiu, Rocío Navarro, Susana Frago, Laura Rubio-Pérez, Laura Rubio-Pérez, Laura Rubio-Pérez, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Laura Díez-Alonso, Laura Díez-Alonso, Laura Díez-Alonso, Marina Gómez-Rosel, Marina Gómez-Rosel, Marina Gómez-Rosel, Noelia Silva-Pilipich, Noelia Silva-Pilipich, Lucía Vanrell, Cristian Smerdou, Cristian Smerdou, Kenneth A. Howard, Laura Sanz, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Marta Compte   +27 more
doaj   +1 more source